InnovAge Holding Corp. (INNV) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, InnovAge Holding Corp. (NASDAQ: INNV) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $9.24 (+1.54% 1D, market cap $1.26B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, INNV ranks #253 in composite RQD confidence.
Within the Health Care sector (Medical/Nursing Services), INNV carries a Roarable D+ (57/100 RQD), trailing P/E of N/A, gross margin of 18.0%, and ROIC of -10.2%. By comparison, USPH (U.S. Physical Therapy Inc.) holds a C grade (64/100 RQD, P/E 32.6x, ROIC 11.5%, cap $1.29B) and OMDA (Omada Health Inc.) posts a D+ grade (56/100 RQD, P/E N/A, ROIC -15.7%, cap $1.20B). Among the 5-stock peer group, USPH leads on earnings multiple (32.6x) while USPH leads on capital efficiency (11.5% ROIC).
Per INNV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001834376), InnovAge Holding Corp. generated $853.7M in revenue (+11.8% YoY), -$30.3M in net income, and $26.6M in free cash flow against $527.5M in total assets and $56.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 61% of 52W Range • RSI-14 at 45.7 (NEUTRAL RANGE)
SEC XBRL FY 2025 (10-K): 3.1% FCF Margin ($26.6M FCF) & 18% Gross Margin
Disciplined Float (+0.16% YoY Shares) & executive Form 4 sales trim 13 pts from alignment
Even with a 57/100 (D+) score, INNV faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($9.84) or 200D SMA ($9.06) invalidates the momentum regime and cuts Target Base ($9.20) toward Bear Floor ($7.18).
InnovAge Holding Corp. (INNV) advanced +1.54% to $9.24, trading at 61% of its 52-week range ($3.94 – $12.64). Stretched risk/reward at current multiples (-10% return on capital) under elevated 10-year interest-rate pressure.
Pediatrix Medical Group (MD) delivered earnings and revenue surprises of +14.29% and +1.79%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
California’s proposed wealth tax has turned the state into a live experiment in how aggressive policy can ripple through portfolios, boardrooms, and hospital corridors at the same time. If ultra-rich shareholders adjust
DENVER, Oct. 20, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, and predominantly dual-eligible s
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +11.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on INNV today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for INNV. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, InnovAge Holding Corp. (INNV) ranks #253 by composite RQD confidence (57/100, grade D+) and #331 by equity capitalization ($1.26B). Within this direct 5-issuer industry benchmark cohort, USPH leads on earnings valuation at 32.6x trailing P/E, while USPH leads on capital efficiency and profitability with 11.5% ROIC and 19.2% gross margin. USPH currently holds the highest overall quantitative score in the immediate peer group at 64/100 (C) compared with INNV at 57/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| INNV
ACTIVE
InnovAge Holding Corp. | D+ | 57/100 | — | 18.0% | -10.2% | +1.54% | $1.26B | Benchmark Subject |
| USPH U.S. Physical Therapy Inc. | C | 64/100 | 32.6x | 19.2% | 11.5% | +1.47% | $1.29B | /usph-vs-innv → |
| OMDA Omada Health Inc. | D+ | 56/100 | — | 65.7% | -15.7% | +2.45% | $1.20B | /omda-vs-innv → |
| PNTG The Pennant Group Inc. | D+ | 56/100 | 50.2x | — | 11.0% | +0.76% | $1.48B | /pntg-vs-innv → |
| TDOC Teladoc Health Inc. | D+ | 56/100 | — | — | -17.0% | +26.89% | $1.59B | /tdoc-vs-innv → |
In its most recent audited fiscal period (FY2025, filed 2025-06-30), InnovAge Holding Corp. (INNV) reported GAAP revenue of $853.7M (+11.8% vs. FY2024 revenue of $763.9M , and +24.1% cumulative change since FY2023) , GAAP net income of -$30.3M, operating cash flow of $32.9M, and free cash flow of $26.6M (+159.4% YoY). On the balance sheet, INNV closed FY2025 with $527.5M in total assets against $56.0M in total debt (Altman Z-Score: 4.47, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-06-30 | $853.7M | -$30.3M | $32.9M | $26.6M | $527.5M | $56.0M |
| FY2024 (FY) | 2024-06-30 | $763.9M | -$21.3M | -$36.9M | -$44.8M | $524.8M | $59.8M |
| FY2023 (FY) | 2023-06-30 | $688.1M | -$40.7M | $20.2M | $20.2M | — | — |
As of 2026-11-01, InnovAge Holding Corp. (NASDAQ: INNV) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $9.24 (+1.54% 1D, market cap $1.26B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, INNV ranks #253 in composite RQD confidence.
Within the Health Care sector (Medical/Nursing Services), INNV carries a Roarable D+ (57/100 RQD), trailing P/E of N/A, gross margin of 18.0%, and ROIC of -10.2%. By comparison, USPH (U.S. Physical Therapy Inc.) holds a C grade (64/100 RQD, P/E 32.6x, ROIC 11.5%, cap $1.29B) and OMDA (Omada Health Inc.) posts a D+ grade (56/100 RQD, P/E N/A, ROIC -15.7%, cap $1.20B). Among the 5-stock peer group, USPH leads on earnings multiple (32.6x) while USPH leads on capital efficiency (11.5% ROIC).
Per INNV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001834376), InnovAge Holding Corp. generated $853.7M in revenue (+11.8% YoY), -$30.3M in net income, and $26.6M in free cash flow against $527.5M in total assets and $56.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
INNV last traded at $9.24 (+1.54% on volume of 585,553 shares), positioning the stock -6.10% below its 50-day simple moving average ($9.84) and +1.99% above its 200-day simple moving average ($9.06). Across its 52-week range of $3.94 to $12.64, INNV sits at the 60.9% percentile with a 14-day RSI of 45.7 (NEUTRAL RANGE) and an implied next-earnings move of ±7.3% ($8.57 to $9.91).
Why INNV Stock advanced +1.54% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-10% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).